Delivery Order SPE2DB22D2108-SPE2DB24FU3PW

Award Date 4/1/24
Potential Completion Date 4/2/24
Potential Value $2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $3,937.95 to provide XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 with a performance period through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen Drug Corp to...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,403.31, is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 7, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,021.23, is a Firm Fixed Price Delivery Order for the pharmaceutical product "XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML". The contract has a completion date of March 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,487.17 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has an ultimate completion date of March 4, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,050.12 delivery order contract is for the supply of the medication XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML. The contract has a firm fixed price pricing type and an ultimate completion date of November 1, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,629.66 firm fixed-price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has an ultimate completion date of January 15, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,024.09, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, to support military healthcare programs. This is a Firm Fixed Price Delivery Order contract with a completion date of November 12, 2024. The contract is not designated as a set-aside....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,110.49 firm fixed-price delivery order is for the procurement of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML medical supplies. The contract has an ultimate completion date of March 4, 2025 and was awarded on March 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is a $1,629.66 Firm Fixed Price Delivery Order from the Defense Logistics Agency (DLA) for the supply of the medication XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML. The contract has an ultimate completion date of March 4, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,157.69, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 16, 2025. This award is not associated with a set-aside designation....
  • SPE2DB22D2108
    Indefinite Delivery Contract
  • SPE2DB22D2108-SPE2DB24FU3PW
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a delivery order with a firm fixed price valued at $2,024.63, with an ultimate completion date of April 2, 2024. The contract provides for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product.

Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This award is not associated with any set-aside designations.

Generated 7/1/24, 9:07 AM